103 related articles for article (PubMed ID: 2990656)
21. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
23. The significance of müllerian inclusions found at second-look laparotomy in patients with epithelial ovarian neoplasms.
Copeland LJ; Silva EG; Gershenson DM; Sneige N; Atkinson EN; Wharton JT
Obstet Gynecol; 1988 May; 71(5):763-70. PubMed ID: 2833713
[TBL] [Abstract][Full Text] [Related]
24. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
Folk JJ; Botsford M; Musa AG
Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
[TBL] [Abstract][Full Text] [Related]
25. Second-look laparotomy in the management of epithelial ovarian carcinoma: an evaluation of fifty cases.
Luesley DM; Chan KK; Fielding JW; Hurlow R; Blackledge GR; Jordon JA
Obstet Gynecol; 1984 Sep; 64(3):421-6. PubMed ID: 6462573
[TBL] [Abstract][Full Text] [Related]
26. Alphafetoprotein and germ cell neoplasms.
Hayatnagarkar NP; Deshpande AD; Solanki BR
Indian J Med Res; 1980 Aug; 72():269-72. PubMed ID: 6164638
[No Abstract] [Full Text] [Related]
27. [Tumor reduction by second-look laparotomy following combined radiochemotherapy in advanced ovarian carcinoma].
Szalay S; Janisch H; Breitenecker G; Szepesi T
Gynakol Rundsch; 1982; 22(2):150-3. PubMed ID: 7201947
[No Abstract] [Full Text] [Related]
28. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
30. [Treatment results in malignant ovarian tumors. (A report of 192 cases)].
Methfessel HD; Köhler L; Methfessel G
Zentralbl Gynakol; 1969 Apr; 91(17):532-6. PubMed ID: 5373784
[No Abstract] [Full Text] [Related]
31. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
Liu LY
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
33. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
34. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer.
Piver MS; Moyer M; Diakun K; Lele SB; Chu TM
Gynecol Oncol; 1988 Mar; 29(3):305-8. PubMed ID: 3345951
[TBL] [Abstract][Full Text] [Related]
35. [Blood serum level of copper in neoplasms of the respiratory tract].
Palukiewicz J; Jakubowski W; Turczynowski R
Gruzlica; 1969 May; 37(5):451-5. PubMed ID: 4308680
[No Abstract] [Full Text] [Related]
36. Significance of tumour markers in ovarian cancer.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
Indian J Cancer; 1987 Mar; 24(1):1-8. PubMed ID: 2448222
[No Abstract] [Full Text] [Related]
37. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Bundy BN; Delgado G; Sevin BU; Creasman WT; Major FJ; Zaino R
Am J Obstet Gynecol; 1992 Jan; 166(1 Pt 1):50-3. PubMed ID: 1733218
[TBL] [Abstract][Full Text] [Related]
38. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy.
Lightman A; Brandes JM; Binur N; Drugan A; Zinder O
Clin Chem; 1986 Jan; 32(1 Pt 1):101-3. PubMed ID: 3940688
[TBL] [Abstract][Full Text] [Related]
39. The significance of measurement of human placental lactogen, human chorionic gonadotropin, and carcinoembryonic antigen in patients with ovarian carcinoma.
Samaan NA; Smith JP; Rutledge FN; Schultz PN
Am J Obstet Gynecol; 1976 Sep; 126(2):186-9. PubMed ID: 183504
[TBL] [Abstract][Full Text] [Related]
40. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
